PTGX

Protagonist Therapeutics is a clinical/commercial-stage biotech that is more de-risked than its loss-making financials suggest. Its two lead assets are both partnered with major pharma and at the regulatory finish line: icotrokinra (Icotyde), a first-in-class oral IL-23R peptide for psoriasis, is licensed to Johnson & Johnson, which filed a US NDA in July 2025 and expects a US launch in 2026; and rusfertide, an injectable hepcidin mimetic for polycythemia vera, is partnered with Takeda, carries Breakthrough Therapy, Fast Track and Orphan Drug designations, had its NDA filed in December 2025, and Takeda expects to launch in 2H 2026. Beyond these, a pipeline spanning IL-17 (PN-881), obesity GLP-1/GIP/GCG candidates (PN-477, PN-458) and oral hepcidin (PN-8047) adds optionality.

The financials reflect a research-stage cost base, not the future royalty/milestone economics. Revenue is intentionally lumpy — $46.0M in FY2025 versus $434M in FY2024 (which booked large collaboration milestones) — and the company posted a net loss of -$130M as R&D rose 15.3% to $159M. Cumulative losses since inception are $470.7 million. Liquidity is adequate: management cites roughly $646.0 million of cash, equivalents and marketable securities at year-end 2025, and the company carries minimal debt (liabilities/equity 0.09x), funding the pipeline while milestone payments accrue.